IN THE SPOTLIGHT

Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled, Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance

Collin M. Blakely and Trever G. Bivona

Summary: The clinical success of EGFR receptor (EGFR) inhibitors in patients with lung cancer is limited by the inevitable development of treatment resistance. Two reports in this issue of Cancer Discovery uncover additional mechanisms by which EGFR-mutant lung cancers escape from EGFR kinase inhibitor treatment. These findings pave the way for clinical testing of new rational therapeutic strategies to prevent or overcome resistance to EGFR kinase inhibitors in the clinic. Cancer Discov; 2(10); 872–5. ©2012 AACR.

Commentary on Ercan et al., p. 934 (7).
Commentary on Takezawa et al., p. 922 (8).

A new paradigm for the development of systemic cancer therapy has emerged over the past decade with the move away from broadly cytotoxic agents to targeted therapies. This has been enabled by the identification of specific alterations that drive oncogenesis in a wide variety of tumor types and the development of small molecules or antibodies that specifically target these “oncogenic drivers.” Cancer cells driven by an oncogene are dependent on its activity for their growth and survival such that the cells die without it (oncogene dependence). Thus, clinical practice has moved into an era of precision medicine in which many patients with cancer are treated with therapies that target a specific driver oncogene in the tumor. Despite the success of oncogene-targeted therapies, single-agent treatment with an inhibitor of an oncogenic driver is not curative in patients (with a few notable exceptions) because of both innate and acquired treatment resistance. This challenge provides strong motivation to discover the molecular mechanisms that tumors use to evade driver oncogene inhibition. The identification of these molecular events pinpoints potential biomarkers of response to oncogene inhibitor treatment and rational therapeutic targets to prevent or overcome resistance to oncogene inhibition in patients.

Lung cancers with activating mutations in the kinase domain of EGFR receptor (EGFR) serve as a paradigm for the field of targeted therapeutics and precision cancer medicine. Tumors from patients with advanced non–small cell lung cancer (NSCLC) are routinely screened for the presence of these mutations in EGFR, which most commonly occur in exons 19 or 21 in the form of an inframe deletion or a point mutation (L858R), respectively. These somatic mutations in EGFR occur in approximately 10% to 30% of patients with NSCLCs (Fig. 1A; ref. 1). In patients with EGFR-mutant lung cancer with advanced disease, treatment with an EGFR kinase inhibitor (erlotinib or gefitinib) is superior to standard cytotoxic chemotherapy and has therefore become first-line therapy (2). Although the vast majority of patients initially respond to EGFR-tyrosine kinase inhibitor (TKI) treatment, acquired resistance to therapy inevitably develops in patients. Prior work by several groups has uncovered the cause of acquired resistance in many cases. In approximately 50% to 60% of cases, the mechanism of acquired resistance to EGFR-TKI therapy is the acquisition of a second site T790M “gatekeeper” mutation in the kinase domain of EGFR, in addition to the primary activating kinase domain mutation (3, 4). The second site T790M mutation in EGFR alters the binding of erlotinib and gefitinib to the ATP-binding pocket and therefore these inhibitors are unable to block EGFR signaling. Other mechanisms of acquired resistance to erlotinib and gefitinib include the following: upregulation of the AXL kinase in approximately 20% to 25% of cases (5); amplification of the MET kinase in approximately 5% of cases (3, 4); activating mutations in the PIK3CA gene in approximately 5% of cases (6); and histologic and phenotypic transformation to small-cell lung cancer in approximately 5% of cases (6). The mechanisms of acquired resistance to first-line EGFR-TKI treatment are unclear in the remaining 15% to 20% of cases. Moreover, the potential ways in which EGFR-mutant lung cancers may evade treatment with next-generation EGFR kinase inhibitors developed to overcome EGFR T790M–driven resistance that are entering into the clinic are unknown. Two elegant studies by Ercan and colleagues (7) and by Takezawa and colleagues (8) in the current issue of Cancer Discovery shed new light on the mechanisms of acquired resistance to EGFR kinase inhibitors.

Ercan and colleagues (7) focus on the clinical problem of EGFR T790M–mediated resistance. In prior work, these authors developed a novel class of EGFR kinase inhibitors based on a pyrimidine scaffold that covalently bind and irreversibly inhibit mutant EGFR, including EGFR T790M, but
Figure 1. Mechanisms of acquired resistance to EGFR inhibitors and emerging pharmacologic approaches to overcome resistance. A, the relative frequency of specific oncogenic driver mutations in lung adenocarcinomas. Red wedge indicates the frequency of somatic activating mutations in EGFR (L858R or in frame exon 19 deletion). B, the spectrum and frequency of known drivers of acquired resistance to EGFR inhibitor therapy in lung cancer. Two new drivers of acquired resistance are described in this issue of Cancer Discovery: MAPK1 amplification was seen in approximately 5% of patients (7) and HER2 amplification in approximately 12% of patients (8). Transformation to small-cell lung cancer and epithelial-to-mesenchymal transition (EMT) have also been described as resistance mechanisms; however, the frequency and degree to which these events drive EGFR-TKI acquired resistance and the molecular pathways underlying these events have not been fully defined. C, schematic of pathways to EGFR inhibitor acquired resistance and pharmacologic approaches in development to overcome them. EGFR T790M mutation is the dominant driver of EGFR inhibitor resistance (50%–60%). Second-generation EGFR-TKI inhibitors BIBW2992 (afatinib), PF299804 (dacomitinib), and WZ4002 covalently bind to EGFR and have shown promise as EGFR T790M inhibitors in preclinical studies. HER2 amplification may promote acquired resistance through heterodimerization with EGFR and activation of downstream signaling events [i.e., extracellular signal-regulated kinase (ERK) and AKT]. The combination of BIBW2992 together with the EGFR monoclonal antibodies cetuximab or panitumumab can inhibit both EGFR and HER2 activity in cellular and murine models of EGFR-mutant-driven lung cancer. MAPK1 amplification leads to increased ERK expression and elevated phospho-ERK levels. This may promote acquired resistance by promoting ERK internalization. Inhibition of mitogen-activated protein–ERK kinase (MEK) activity by GSK-1120212 decreases ERK phosphorylation and overcomes acquired resistance driven by ERK overexpression in cellular and murine models. Upregulation of AXL kinase activity occurs in 20% to 25% of patients with acquired resistance to EGFR inhibitors and may act through downstream effectors including NF-κB and AKT or by promoting EMT. XL-880 is an AXL inhibitor in clinical development that can overcome AXL-mediated resistance to erlotinib in models of EGFR-mutant lung cancer. MET amplification and PIK3CA mutations have been described in approximately 5% of patients with acquired resistance. Several MET and phosphoinositide 3-kinase (PI3K) inhibitors are in clinical development and testing.
not wild-type EGFR (9). These inhibitors, which include a lead candidate, WZ4002, are thus mutant selective and were designed to circumvent the limitations of other irreversible EGFR inhibitors, including BIBW2992 (afatinib; ref. 10) and PF299804 (dacomitinib; ref. 11). In the current report, Ercan and colleagues (7) used several established human cell line models of EGFR-mutant lung cancer to determine the molecular events that could lead to resistance to WZ4002 treatment in EGFR-mutant lung cancers. These researchers used a previously established isogenic model of acquired resistance to gefitinib that contains an EGFR exon 19 deletion/T790M compound mutant and exposed the cells to prolonged WZ4002 treatment to establish individual clones resistant to WZ4002 (WZR cells). Treatment of the WZR cells with WZ4002 resulted in suppression of EGFR phosphorylation; however, the authors noted persistently elevated levels of both phosphorylated and total extracellular signal–regulated kinase (ERK)2. Through genome-wide copy number analysis, the authors found that total extracellular signal–regulated kinase (ERK)2. Through

Moreover, downregulation of several negative regulators of MAPK signaling, including the dual specificity phosphatase 6 (DUSP6), in the absence of MAPK1 amplification, was found as a potential alternative mechanism of acquired resistance to EGFR-TKI treatment. Treatment with an allosteric MEK inhibitor restored EGFR-TKI sensitivity in cellular and murine models of acquired resistance to EGFR-TKI treatment that had increased MAPK1 amplification. Notably, combination therapy with WZ4002 and an MEK inhibitor prevented the emergence of resistance in EGFR-mutant lung cancer cellular models in vitro. Mechanistic studies revealed that MAPK1 amplification could promote EGFR-TKI resistance, at least in part, by enhancing internalization of EGFR. To clinically validate the preclinical findings, the authors investigated whether MAPK1 amplification occurred in clinical lung cancer specimens. Indeed, MAPK1 amplification was found in approximated 5% (1 of 21) of clinical specimens from patients with acquired resistance to EGFR-TKI treatment and in which there was no evidence of EGFR T790M or MET amplification. Together the data indicate that hyperactivation of MAPK signaling can promote acquired resistance to EGFR-TKI treatment. Additional studies are warranted to determine the full extent to which MAPK1 activation, either through MAPK1 amplification or downregulation of DUSP6 or other negative regulators of MAPK signaling, occurs in patients with EGFR-mutant lung cancer with acquired EGFR-TKI resistance. Collectively, the data provide rationale for clinical testing of a mitogen-activated protein–ERK kinase (MEK) inhibitor in combination with WZ4002 or other EGFR-TKIs to prevent or overcome EGFR-TKI resistance in patients with EGFR-mutant lung cancer.

The companion study by Takezawa and colleagues (8) complements the work of Ercan and colleagues (7) and moves the field forward in parallel by uncovering a potential role for HER2 in acquired resistance to EGFR inhibitor treatment in EGFR-mutant lung cancers that do not harbor the EGFR T790M resistance mutation. The authors set out to determine a molecular basis for the apparent synergistic effects of treat-
of more effective therapeutic strategies to enhance clinical responses. By extension, the analysis of similar cohorts of clinical specimens from patients with other EGFR-driven cancers who are treated with EGFR-driven inhibitors could address whether MAPK1 or HER2 amplification may lead to resistance in additional clinical contexts.

Second, the clonal dynamics of the emergence or appearance of MAPK1 or HER2 upregulation remain to be clarified. Do these molecular events preexist in minor frequencies in tumors before therapy and emerge during the selective pressure of EGFR-TKI treatment, as suggested for the presence of the EGFR T790M resistance allele (3, 4)? Or does EGFR-TKI treatment directly or indirectly induce the de novo appearance of MAPK1 or HER2 amplification or activation in the tumors? Novel applications of next-generation sequencing methodologies and single-cell analysis of tumor cells within a population may provide answers to these unresolved questions.

Third, do we now have a complete picture of the ways in which EGFR-mutant lung cancers can escape from EGFR-TKI treatment based on the findings reported here and several prior studies (3, 4)? A more comprehensive analysis of clinical specimens from EGFR-TKI–treated patients should offer deeper insight into the degree to which the known mechanisms of resistance occur exclusively and concomitantly to promote clinical resistance. This is a key issue to resolve to clinically implement the identification of resistance mechanisms because we will need to determine whether to target individual or multiple drivers of resistance with targeted therapies in patients classified according to the molecular alterations present in their tumors. Such efforts should also clarify whether there are high frequency alterations in EGFR-TKI–resistant lung cancers that have not yet been identified or whether only lower frequency or private molecular events that contribute to resistance in individual patients remain to be uncovered.

Each of these unresolved issues relates directly to how the deeper understanding of the events that lead to EGFR inhibitor resistance could be leveraged to improve outcomes for patients with lung cancer. Clinical trials that test whether inhibition of MAPK signaling, HER2, or other drivers of resistance improves clinical outcomes in EGFR-TKI–treated patients with lung cancer will need to incorporate validated molecular tests conducted on clinical samples to identify the secondary resistance alterations. This will enable molecular stratification of patients to the therapy(ies) targeted against the resistance driver(s). The challenge is to develop molecular testing for resistance drivers that is comprehensive, standardized, and also practical to facilitate widespread clinical testing of biomarker-driven therapeutic strategies in patients. Ultimately, the best way to overcome acquired resistance to any therapy is to prevent it from occurring in the first place. Thus, biomarker-driven clinical studies testing appropriate companion therapies in the upfront setting are also warranted, as suggested by Erkan and colleagues (7). Mechanisms of resistance to targeted therapy are coming into full view in lung and other cancers. The challenge and hope is that we can capitalize on the knowledge gained and, through mechanism-based clinical trials, divide and conquer the molecular basis of resiliency that allows oncogene-driven tumors to evade our initial precision attack.

Disclosure of Potential Conflicts of Interest

T.G. Bivona is a consultant and advisory board member of Cancer Therapeutics Innovation Group. No potential conflicts of interest were disclosed by the other author.

Received August 20, 2012; accepted August 24, 2012; published online October 15, 2012.

REFERENCES

Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled, Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance

Collin M. Blakely and Trever G. Bivona


Access the most recent version of this article at:
http://cancerdiscovery.aacrjournals.org/content/2/10/872

This article cites 11 articles, 3 of which you can access for free at:
http://cancerdiscovery.aacrjournals.org/content/2/10/872.full#ref-list-1

Sign up to receive free email-alerts related to this article or journal.

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.